GLP-1 drugs are rapidly transforming the treatment of obesity, diabetes and a growing range of chronic conditions, offering new promise for improved health outcomes. However, the unprecedented growth of compounded drugs are raising questions about regulation enforcement, safety and oversight, and the potential impact of newer distribution models.
Join Axios Live in Washington, D.C., for an event examining the evolving GLP-1 landscape. We’ll talk about the promise of these therapies, the risks and regulatory challenges surrounding non-FDA approved compounded versions, and what the next phase could mean for patients, providers, policymakers and industry.
Subscribe to Axios Vitals: Keep up with health care politics, policy and business by Tina Reed and Maya Goldman. With future focused sends by Caitlin Owens.
